Risk factors for atrial fibrillation include high blood pressure, heart disease, diabetes, obesity, excessive alcohol consumption, and a family history of AF.
Hightower Clinical is committed to driving progress in treating atrial fibrillation and enhancing patient care globally.
Atrial Fibrillation (AF) is a common heart condition characterized by an irregular heart rhythm in the upper chambers (atria). Afib is one of the common types of arrythmias and present symptoms like fatigue, palpitations, difficulty in breathing, and dizziness.
Hightower Clinical conducted a study to evaluate the safety and effectiveness of the Amulet Left Atrial Appendage (LAA) occlusion device as an alternative to NOAC therapy in patients with non-valvular AF at increased risk for stroke. The goal was to provide insight into whether the device can be a safer and more effective long-term option for stroke prevention compared to NOACs.
Not Recruiting
1
Study Name | Protocol Number | Sponsor |
---|---|---|
Atrial Fibrillation | ABT-CIP-10310 | Abbott |
Risk factors for atrial fibrillation include high blood pressure, heart disease, diabetes, obesity, excessive alcohol consumption, and a family history of AF.
Atrial fibrillation can lead to serious complications, including an increased risk of stroke, heart failure, and blood clots.
Participating in a clinical trial can give you access to new treatments and help advance medical research, potentially improving care for yourself and others with atrial fibrillation.
Eligibility depends on factors like your type of atrial fibrillation, medical history, and whether you’re already receiving treatment like NOAC therapy.